Last reviewed · How we verify
Xuezhikang capsule
Xuezhikang reduces blood lipids and improves blood circulation by inhibiting cholesterol synthesis and modulating lipid metabolism through its active compounds derived from red yeast rice.
Xuezhikang reduces blood lipids and improves blood circulation by inhibiting cholesterol synthesis and modulating lipid metabolism through its active compounds derived from red yeast rice. Used for Hyperlipidemia and dyslipidemia, Coronary artery disease prevention and secondary prevention, Atherosclerosis.
At a glance
| Generic name | Xuezhikang capsule |
|---|---|
| Also known as | XZK |
| Sponsor | China Academy of Chinese Medical Sciences |
| Drug class | Herbal lipid-lowering agent; statin-containing traditional Chinese medicine |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Xuezhikang is a traditional Chinese medicine preparation derived from fermented red yeast rice (Monascus purpureus) that contains naturally occurring statins and other bioactive compounds. It lowers LDL cholesterol and triglycerides while raising HDL cholesterol, and also exhibits antiplatelet and antithrombotic properties that improve microcirculation and reduce cardiovascular risk.
Approved indications
- Hyperlipidemia and dyslipidemia
- Coronary artery disease prevention and secondary prevention
- Atherosclerosis
Common side effects
- Gastrointestinal upset
- Muscle pain or myalgia
- Headache
- Liver enzyme elevation
Key clinical trials
- The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin：Comparing With Standardized Statin (PHASE3)
- Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes (PHASE4)
- Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers (PHASE1)
- Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia (PHASE2)
- A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xuezhikang capsule CI brief — competitive landscape report
- Xuezhikang capsule updates RSS · CI watch RSS
- China Academy of Chinese Medical Sciences portfolio CI